VBL Therapeutics

Company Overview

Snapshot

Founded in January 2000 by Dror Harats, VBL Therapeutics operated with 11–50 employees. The company raised a total of $109.77 million across 5 funding rounds from 8 investors. In February 2023, VBL Therapeutics was acquired by Notable Labs.

Business overview

VBL Therapeutics is a biopharmaceutical company focused on developing targeted therapies for immune-inflammatory diseases. The company's core technology revolves around its Monocyte Targeting Technology (MTT), which aims to limit chronic inflammation by targeting the MOSPD2 ("mono-walk") receptor on monocytes. Its lead MTT candidate, VB-601, is an investigational monoclonal antibody designed to block monocytes from reaching inflamed tissues. VBL Therapeutics serves the pharmaceutical and life sciences sectors, with potential applications in various immune-inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and non-alcoholic steatohepatitis (NASH).

Strategic signal

In February 2023, VBL Therapeutics announced a definitive merger agreement with Notable Labs. This acquisition signifies a strategic shift for VBL Therapeutics, transitioning from an independent entity to becoming part of a larger biopharmaceutical organization. For investors, this indicates a consolidation within the health tech and life sciences sector, potentially leading to new development pathways for VBL's therapeutic candidates under Notable Labs' umbrella.

Company Intelligence Q&A

What was a significant corporate event for VBL Therapeutics in early 2023?

In February 2023, VBL Therapeutics announced a definitive merger agreement with Notable Labs, leading to its acquisition.

What was the outcome of VBL Therapeutics' Phase 3 OVAL trial in July 2022?

In July 2022, VBL Therapeutics announced top-line data from its Phase 3 OVAL trial of Ofra-Vec in patients with platinum-resistant ovarian cancer, which did not meet its primary endpoint.

What strategic action did VBL Therapeutics take in August 2022?

In August 2022, VBL Therapeutics announced a workforce reduction and initiated a corporate process to explore strategic options following the results of its OVAL trial.

What was a key development for VBL Therapeutics' VB-601 program in September 2020?

In September 2020, VBL Therapeutics successfully completed a Pre-IND meeting with the FDA regarding the proposed clinical development of VB-601, its lead.

What patent milestone did VBL Therapeutics achieve in October 2020?

In October 2020, VBL Therapeutics announced an additional new European patent in its MOSPD2 platform technology for the treatment of cancer, further protecting its anti-MOSPD2 antibodies for inflammation until at least July 2036.